Butyrylcholinesterase in guinea pig lung lavage: A novel biomarker to assess lung injury following inhalation exposure to nerve agent VX

Inhalation Toxicology

Volumn 18, Issue 7, 2006, Pages 493-500

  Graham, Jacob R ^a   Wright, Benjamin S ^a   Rezk, Peter E ^a   Gordon, Richard K ^a   Sciuto, Alfred M ^b   Nambiar, Madhusoodana P ^a,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BIOLOGICAL MARKER; CHEMICAL WARFARE AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HUPERZINE A; ISO OMPA; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; EXPOSURE; FEMALE; GUINEA PIG; LUNG ENDOTHELIUM; LUNG INJURY; LUNG INTERSTITIUM; LUNG LAVAGE; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE HOMOGENATE;

ACETYLCHOLINESTERASE; ANIMALS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BUTYRYLCHOLINESTERASE; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; FEMALE; GUINEA PIGS; INHALATION EXPOSURE; LUNG; MALE; ORGANOTHIOPHOSPHORUS COMPOUNDS;

ANIMALIA; CAVIA; CAVIA PORCELLUS;

EID: 33645784000     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.1080/08958370600602116     Document Type: Article

References (38)

1. Abdel-Rahman, A., Shetty, A. K., and Abou-Donia, M. B. 2002. Acute exposure to sarin increases blood brain barrier permeability and induces neuropathological changes in the rat brain: Dose-response relationships. Neuroscience 113:721-741.
2. Anthony, J. S., Haley, M., Manthei, J., Way, R., Burnett, D., Gaviola, B., Sommerville, D., Crosier, R., Mioduszewski, R., Thomson, S., Crouse, C., and Matson, K. 2004. Inhalation toxicity of cyclosarin (GF) vapor in rats as a function of exposure concentration and duration: Potency comparison to sarin (GB). Inhal. Toxicol. 16:103-111.
3. Ashani, Y., Shapira, S., Levy, D., Wolfe, A. D., Doctor, B. P., and Raveh, L. 1991. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 41:37-41.
4. Bajgar, J., Sevelova, L., Krejcova, G., Fusek, J., Vachek, J., Kassa, J., Herink, J., De Jong, L. P., and Benschop, H. P. 2004a. Biochemical and behavioral effects of soman vapors in low concentrations. Inhal. Toxicol. 16:497-507.
5. Bajgar, J., Sevelova, L., Krejcova, G., Fusek, J., Vachek, J., Kassa, J., Herink, J., De Jong, L. P., and Benschop, H. P. 2004b. Biochemical and behavioral effects of soman vapors in low concentrations. Inhal. Toxicol. 16:497-507.
6. Benschop, H. P., Trap, H. C., Spruit, H. E., van der Wiel, H. J., Langenberg, J. P., and De Jong, L. P. 1998. Low level nose-only exposure to the nerve agent soman: Toxicokinetics of soman stereoisomers and cholinesterase inhibition in atropinized guinea pigs. Toxicol. Appl. Pharmacol. 153:179-185.
7. Bide, R. W., and Risk, D. J. 2004. Inhalation toxicity in mice exposed to sarin (GB) for 20-720 min. J. Appl. Toxicol. 24:459-467.
8. Buchanan, K. C., Burge, R. R., and Ruble, G. R. 1998. Evaluation of injectable anesthetics for major surgical procedures in guinea pigs. Contemp. Top. Lab. Anim. Sci. 37:58-63.
9. Cohan, S. L., Pohlmann, J. L., Mikszewski, J., and O'Doherty, D. S. 1976. The pharmacokinetics of pyridostigmine. Neurology 26:536-539.
10. Damodaran, T. V., Jones, K. H., Patel, A. G., and Abou-Donia, M. B. 2003. Sarin (nerve agent GB)-induced differential expression of mRNA coding for the acetylcholinesterase gene in the rat central nervous system. Biochem. Pharmacol. 65:2041-2047.
11. DeLorenzo, R. A. 2001. Exposed. Signs, symptoms & EMS management of nerve-agent poisoning. J Emerg. Med. Serv. 26:48-57.
12. Doctor, B. P., and Saxena, A. 2005. Bioscavengers for the protection of humans against organophosphate toxicity. Chem. Biol. Interact. 157-158:167-171.
13. Doctor, B. P., Toker, L., Roth, E., and Silman, I. 1987. Microtiter assay for acetylcholinesterase. Anal. Biochem. 166:399-403.
14. Doctor, B. P., Raveh, L., Wolfe, A. D., Maxwell, D. M., and Ashani, Y. 1991. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci. Biobehav. Rev. 15:123-128.
15. Ellman, G. L., Courtney, K. D., Andres, V., Jr., and Feather-Stone, R. M. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:88-95.
16. Feaster, S. R., and Quinn, D. M. 1997. Mechanism-based inhibitors of mammalian cholesterol esterase. Methods Enzymol. 286:231-252.
17. Feaster, S. R., Lee, K., Baker, N., Hui, D. Y., and Quinn, D. M. 1996. Molecular recognition by cholesterol esterase of active site ligands: Structure-reactivity effects for inhibition by aryl carbamates and subsequent carbamylenzyme turnover. Biochemistry 35:16723-16734.
18. Gordon, R. K., Feaster, S. R., Russell, A. J., LeJeune, K. E., Maxwell, D. M., Lenz, D. E., Ross, M., and Doctor, B. P. 1999. Organophosphate skin decontamination using immobilized enzymes. Chem. Biol. Interact. 119-120:463-470.
19. Gordon, R. K., Haigh, J. R., Garcia, G. E., Feaster, S. R., Riel, M. A., Lenz, D. E., Aisen, P. S., and Doctor, B. P. 2005. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem. Biol. Interact. 157-158:239-246.
20. Jimmerson, V. R., Shih, T. M., Maxwell, D. M., Kaminskis, A., and Mailman, R. B. 1989. The effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2- oxide on tissue cholinesterase and carboxylesterase activities of the rat. Fundam. Appl. Toxicol. 13:568-575.
21. Kadivar, H., and Adams, S. C. 1991. Treatment of chemical and biological warfare injuries: Insights derived from the 1984 Iraqi attack on Majnoon Island. Mil. Med. 156:171-177.
22. Karalliedde, L., Gauci, C. A., and Carter, M. 1991. Chemical weapons. Br. Med. J. 302:474.
23. Kropp, T., and Richardson, R. 2003. Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase. J. Toxicol. Environ. Health A 66:1145-1157.
24. Langenberg, J. P., Spruit, H. E., van der Wiel, H. J., Trap, H. C., Helmich, R. B., Bergers, W. W., van Helden, H. P., and Benschop, H. P. 1998. Inhalation toxicokinetics of soman stereoisomers in the atropinized guinea pig with nose-only exposure to soman vapor. Toxicol. Appl. Pharmacol. 151:79-87.
25. Logan, T. P., Millard, C. B., Shutz, M., Schulz, S. M., Lee, R. B., and Bongiovanni, R. 1999. Cutaneous uptake of 14C-HD vapor by the hairless guinea pig. Drug Chem. Toxicol. 22:375-387.
26. Magnotti, R. A., Jr., Eberly, J. P., Quarm, D. E., and McConnell, R. S. 1987. Measurement of acetylcholinesterase in erythrocytes in the field. Clin. Chem. 33:1731-1735.
27. Masuda, N., Takatsu, M., Morinari, H., and Ozawa, T. 1995. Sarin poisoning in Tokyo subway. Lancet 345:1446.
28. Maxwell, D. M., and Brecht, K. M. 2001. Carboxylesterase: Specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds. J. Appl. Toxicol. 21(suppl 1):S103-S107.
29. Niven, A. S., and Roop, S. A. 2004. Inhalational exposure to nerve agents. Respir. Care Clin. North Am. 10:59-74.
30. Okumura, T., Takasu, N., Ishimatsu, S., Miyanoki, S., Mitsuhashi, A., Kumada, K., Tanaka, K., and Hinohara, S. 1996. Report on 640 victims of the Tokyo subway sarin attack. Ann. Emerg. Med. 28:129-135.
31. Racke, K., and Matthiesen, S. 2004. The airway cholinergic system: Physiology and pharmacology. Pulmon. Pharmacol. Ther. 17:181-198.
32. Raveh, L., Ashani, Y., Levy, D., De La, H. D., Wolfe, A. D., and Doctor, B. P. 1989. Acetylcholinesterase prophylaxis against organophosphate poisoning. Quantitative correlation between protection and blood-enzyme level in mice. Biochem. Pharmacol. 38:529-534.
33. Ray, R., Clark, O. E., III, Ford, K. W., Knight, K. R., Harris, L. W., and Broomfield, C. A. 1991. A novel tertiary pyridostigmine derivative [3-(N,N-dimethylcarbamyloxy)-1-methyl-delta 3-tetrahydropyridine]: Anticholinesterase properties and efficacy against soman. Fundam. Appl. Toxicol. 16:267-274.
34. Saxena, A., Sun, W., Luo, C., and Doctor, B. P. 2005. Human serum butyrylcholinesterase: In vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem. Biol. Interact. 157-158:199-203.
35. Shih, T. M., and McDonough, J. H., Jr. 1999. Organophosphorus nerve agents-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment. Pharmacol. Biochem. Behav. 64:147-153.
36. van Helden, H. P., Trap, H. C., Kuijpers, W. C., Oostdijk, J. P., Benschop, H. P., and Langenberg, J. P. 2004. Low-level exposure of guinea pigs and marmosets to sarin vapour in air: Lowest-observable-adverse-effect level (LOAEL) for miosis. J. Appl. Toxicol. 24:59-68.
37. Wessler, I. K., and Kirkpatrick, C. J. 2001. The non-neuronal cholinergic system: An emerging drug target in the airways. Pulmon. Pharmacol. Ther. 14:423-434.
38. Wessler, I., Kirkpatrick, C. J., and Racke, K. 1998. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: Expression and function in humans. Pharmacol. Ther. 77:59-79.